Worldwide Director, New Technologies
DePuy Synthes Biomaterials
Why I'm a JPAL
I am interested in helping companies successfully develop innovative and transformative technologies and products that provide clinical benefit for the patients and clinicians that we all seek to serve.
Doug is responsible for identifying and assessing new, innovative, and transformative chemical, biological, pharmacological, and materials-based technologies that offer potential clinical value for the patients and physicians that DePuy Synthes serves across its orthopaedic businesses. He then partners with DePuy Synthes R&D, regulatory, clinical, marketing, and JnJ Innovation experts to define and execute on the best paths forward to translate the most innovative solutions to the clinic and into the DePuy Synthes portfolio. Prior to his current position, Doug led biomaterials research and development teams at Synthes. Doug previously led research and development programs in both the medical device and pharmaceutical industries, including anti-infective preclinical drug development at Achillion Pharmaceuticals and the development of innovative biomaterials in the Life Sciences division at United States Surgical Corporation. Doug has a Masters in Medicinal Chemistry from the University of Texas, a PhD in Pharmaceutical Chemistry from the University of California in San Francisco, and was an American Cancer Society post-doctoral fellow in the Department of Biology at the Massachusetts Institute of Technology.